Seleccted Pu
ublicattions Citing Surveyoor® Nucleasefor Mutati
M
on Detection and Analysis
www.IDTDN
NA.comm/Surveeyor
Paper Subject
S
Areea
Selected Publications
P
Ciiting Surveyor® Nuclease for Mutation D
Detection and Analysis ................................... 1
Oncology...................................................................................................... .................................................. 2ne Genetic Screening ........................................................................ .................................................. 3
Germlin
Mitochondrial DNA Analysis
A........................................................................ .................................................. 4
Plant Biology ................................................................................................ .................................................. 4
Microbiology................................................................................................ .................................................. 5
or Nuclease use with TALE Nucleases ............................................... .................................................. 5
Surveyo
Surveyoor Nuclease use with Zinc Finger
F
Nucleases ..................................... .................................................. 5
Synthettic Gene Errorr Correction .................................................................. .................................................. 6
Other Surveyor
S
Nuclease Applicattions......................................................... .................................................. 6

1|PageOncoology
DHPLLC/SURVEYOR Nuclease:N
A Se
ensitive, Rapid and AffordableeMethhod to Analyze BRCA1 and BR
RCA2 Mutation
ns in Breast Cancer
Famillies.
Pilatoo B, De Summa S, Danza K, Papadimitriou S, Zaccagna
Z
P,
Parad
diso A, Tommassi S.
Mol B
Biotechnol. Novv 10 (2011). [Eppub ahead of prrint]
Phosp
phatidyl‐inositol‐3‐kinase alp
pha catalytic su
ubunit mutatioonand reesponse to neo
oadjuvant endocrine therapyy for estrogenrecep
ptor positive brreast cancer.
Ellis M
MJ, Lin L, Crowd
der R, Tao Y, Ho
oog J, Snider J, Davies S,
DeSchhryver K, Evanss DB, Steinseife
er J, Bandaru R, Liu W, Gardne
erH, Semmiglazov V, Waatson M, Hunt K, Olson J, Baseelga J.
Breasst Cancer Res. Treat.
T
119, 379‐390 (2010).
Detecction of androggen receptor mutations
min cirrculating tumoorcells iin castration‐reesistant prosta
ate cancer.
Jiang Y, Palma JF, Aggus DB, Wang Y,
Y Gross ME.
Clin. C
Chem. 58, 1492
2‐1495 (2010).
Assocciations between polycyclic aromaticahydroocarbon‐relateddexpossures and p53 mutations in breastb
tumors.
Morddukhovich I, Rosssner P Jr, Terry MB, Santella R, Zhang YJ,
Hibsh
hoosh H, Memeeo L, Mansukhaani M, Long CM
M, Garbowski G,
GAgraw
wal M, Gaudet MM, Steck SE, Sagiv SK, Eng SM,
S Teitelbaumm
SL, Neeugut AI, Conw
way‐Dorsey K, Gammon
G
MD.
Enviroon Health Persp
pect. 118, 511‐‐8 (2010).
Nonin
nvasive detection of EGFR T7
790M in gefitinib or erlotinib
resisttant non‐small cell lung canceer.
Kuangg Y, Rogers A, Yeap
Y
BY, Wang L, Makrigiorgo
os M, Vetrand K,K
Thied
de S, Distel RJ, Jänne PA.
Clin C
Cancer Res. 15, 2630‐6 (2009)..
Strainn‐specific spontaneous and NNK‐mediatedNtumorigenesists in
Pten++/‐ mice.
Hollannoila RI, Anver MR,
M
nder MC, Baloggh AR, Liwanagg J, Han W, Linn
Dennis PA.
872 (2008).
Neoplasia 10, 866‐8
olymorphisms,, apoptosis, andd theSinglee nucleotide po
devellopment of sevvere late adverrse effects after radiotherapyy.
Azria D, Ozsahin M, Kramar A, Peteers S, Atencio DP,
D Crompton NE,
N
nex F, Pèlegrin A,
A Dubois JB, Mirimanoff
M
RO, Rosenstein BS..
Morn
Clin. C
Cancer Res. 14,, 6284‐6288 (20
008).
Impro
oved identifica
ation of von Hip
ppel‐Lindau gene alterations inclear cell renal tumo
ors.
Nickeerson ML, Jaege
er E, Shi Y, Durocher JA, Mahurrkar S, Zaridze D,
D
Matveeev V, Janout V,
V Kollarova H, Bencko
B
V, Navraatilova M,
Szeszeenia‐Dabrowskka N, Mates D, Mukeria
MA, Holcatova I, Schmiidt
LS, Tooro JR, Karami S,
S Hung R, Gerard GF, Linehan WM, Merino M,
M
Zbar B
B, Boffetta P, Brennan P, Rothman N, Chow WH,
W Waldman FM,
Moorre LE.
Clin C
Cancer Res. 14, 4726‐34 (20088).

Mutatiions in the LKB
B1 tumour supppressor are frequently
detecteed in tumours from Caucasiaan but not Asiann lung cancer
patients.
Koivunnen JP, Kim J, Leee J, Rogers AM
M, Park JO, Zhaoo X, Naoki K,
Okamooto I, Nakagawaa K, Yeap BY, M
Meyerson M, Wo
ong KK,
Richardds WG, Sugarb
baker DJ, Johnso
on BE, Jänne PA
A.
Br. J. CCancer. 99, 245‐‐52 (2008).
TP53 mmutations and ssurvival in squaamous‐cell carrcinoma of thehead aand neck.
ML, Manola J, G
Poeta M
Goldwasser MA
A, Forastiere A,, Benoit N,
Califanno JA, Ridge JA, Goodwin J, Kenady D, Saundeers J, Westra W,
W
Sidranssky D, Koch WM
M.
N. Engl. J. Med. 357, 22552‐61 (2007)).
Surveyyor nuclease‐baased detectionn of p53 gene mmutations inhaemaatological maliggnancy.
Mitani N, Niwa Y, Okaamoto Y.
Clin. Biochem. 444, 557‐9 (2007)
7).
Ann. Cl
KIT‐neggative undiffeerentiated end
dometrial sarccoma with theampliffied epidermall growth facto
or receptor geene showing atempoorary response to Imatinib meesylate.
Mitsuhhashi T, Nakayama M, Sakurai S, Fujimura M, Shimizu Y, BannS, Ogaw
wa F, Hirose T, Ishihara O, Shimmizu M.
Ann. D
Diagn. Pathol. 11, 49‐54 (2007)7).
Allelic dilution obscu
ures detection oof a biologicallyy significant
resistaance mutation in EGFR ‐amplified lung canccer.
Engelmman JA, Mukohaara T, Zejnullah
hu K, Lifshits E, B
Borras AM,
Gale CM
M, Naumov GN
N, Yeap BY, Jarrell E, Sun J, Traccy S, Zhao X,
Heymaach JV, Johnson
n BE, Cantley LCC, Jänne PA.
J. Clin. Invest. 116, 26695‐2706 (20066).
Erlotinnib for frontlinee treatment of advanced non‐‐small cell lungg
cancerr: a phase II studdy.
Giaccoone G, Gallegos Ruiz M, Le Cheevalier T, Thatch
her N, Smit E,
Oulid‐Aissa D, SSoria J.
Rodriguez J, Jänne P, O
06).
Clin. Caancer Res. 12, 66049‐6055 (200Genetiic predictors off adverse radio
otherapy effectts: theGene‐PPARE project.
Ho A, A
Atencio D, Peteers S, Stock R, Fo
ormenti S, Cesaaretti J, GreenS, Hafft
fty B, Drumea KK, Leitzin L, Kuteen A, Azria D, O
Ozsahin M,
Overgaaard J, Andreasssen C, Trop C, Park J, Rosensttein B.
Int. J. R
Radiat. Oncol. B
Biol. Phys. 65, 6
646‐655 (2006).
Responnse and resistaance in a non‐ssmall‐cell lung ccancer patientt
with ann epidermal grrowth factor reeceptor mutatio
on andleptommeningeal metaastases treatedd with high‐dosse gefitinib.
Jackmaan D, Holmes A
A, Lindeman N, W
Wen P, Kesari SS, Borras A,
Bailey CC, de Jong F, Jänne P, Johnson
n B.
J. Clin. Oncol. 24, 45117‐4520 (2006)..

2|PageOncology continued
Exon 19 deletion mutations of epidermal growth factor receptor
are associated with prolonged survival in non‐ small cell lungcancer patients treated with Gefitinib or Erlotinib.
Jackman D, Yeap B, Sequist L, Lindeman N, Holmes A, Joshi V, Bell D,
Huberman M, Halmos B, Rabin M, Haber D, Lynch T, Meyerson M,
Johnson B, Jänne P.
Clin. Cancer Res. 12, 3908‐3914 (2006).
The JAK2 V617F mutation occurs in hematopoietic stem cells inpolycythemia vera and predisposes toward erythroid
differentiation.
Jamieson C, Gotlib J, Durocher J, Chao M, Mariappan M, Lay M,
Jones C, Zehnder J, Lilleberg S, Weissman I.
Proc. Natl. Acad. Sci. 103, 6224‐6229 (2006).
A rapid and sensitive enzymatic method for epidermal growth
factor receptor mutation screening.
Jänne P, Borras A, Kuang Y, Rogers A, Joshi V, Liyanage H, Lindeman
N, Lee J, Halmos B, Maher E, Distel R, Meyerson M, Johnson B.
Clin. Cancer Res. 12, 751‐758 (2006).
Effect of epidermal growth factor receptor tyrosine kinasedomain mutations on the outcome of patients with non‐ small celllung cancer treated with epidermal growth factor receptor
tyrosine kinase inhibitors.
Jänne P, Johnson B.
Clin. Cancer Res. 12, 4416s‐4420s (2006).
Immunohistochemical evaluation of KIT expression in sarcomas of
the gynecologic region.
Nakayama M, Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Ishihara O,
Shimizu M.
Int. J. Gnecol. Pathol. 25, 70‐76 (2006).
Mutation analysis of hCDC4 in AML cells identifies a new
intronic polymorphism.
Nowak D, Mossner M, Baldus C, Hopfer O, Hofmann W.
Int. J. Med. Sci. 3, 148‐151 (2006).
A sensitive high‐throughput method to detect activating
mutations of Jak2 in peripheral‐blood samples.
Sattler M, Walz C, Crowley B, Lengfelder E, Jänne P, Rogers A,
Kuang Y, Distel R, Reiter A, Griffin J.
Blood 107, 1237‐1238 (2006).
Activity of the tyrosine kinase inhibitor PKC412 in a patient withmast cell leukemia with the D816V KIT mutation.
Gotlib J, Berube C, Growney J, Chen C, George T, Williams C,
Kajiguchi T, Ruan J, Lilleberg S, Durocher J, Lichy J, Wang Y, Cohen P,
Arber D, Heinrich M, Neckers L, Galli S, Gilliland D, Coutre S. Blood
106, 2865‐2870 (2005).

Germline Genetic Screening
Mutation analysis of 18 nephronophthisis associated ciliopathy
disease genes using a DNA pooling and next generation
sequencing strategy.
Otto E, Ramaswami G, Janssen S, Chaki M, Allen S, Zhou W, AirikR, Hurd T, Ghosh A, Wolf M, Hoppe B, Neuhaus T, Bockenhauer
D, Milford D, Soliman N, Antignac C, Saunier S, Johnson C,
Hildebrandt F; GPN Study Group.
J Med Genet. 48, 105‐116 (2011).
A molecular analysis of mutations at the complex dumpy locus
in Drosophila melanogaster.
Carmon A, Guertin M, Grushko O, Marshall B, MacIntyre R.
PLoS ONE 5, e12319 (2010).
Meganucleases can restore the reading frame of a mutateddystrophin.
Chapdelaine P, Pichavant C, Rousseau J, Pâques F, Tremblay J.
Gene Ther. 17, 846‐58 (2010).
Screening for mutations in kidney‐related genes using
SURVEYOR nuclease for cleavage at heteroduplex mismatches.
Voskarides K, Deltas C.
J. Mol. Diagn. 11, 311‐318 (2009).
Rapid screening for nuclear genes mutations in isolated
respiratory chain complex I defects.
Pagniez‐Mammeri H, Lombes A, Brivet M, Ogier‐de Baulny H,
Landrieu P, Legrand A, Slama A.
Mol. Genet. Metab. 96, 196‐200 (2009).
Novel method for genomic analysis of PKD1 and PKD2
mutations in autosomal dominant polycystic kidney disease.
Tan YC, Blumenfeld JD, Anghel R, Donahue S, Belenkaya R, Balina
M, Parker T, Levine D, Leonard DG, Rennert H.
Hum. Mutat. 30 264‐273 (2009).
Comparison of the mismatch‐specific endonuclease methodand denaturing high‐performance liquid chromatography for theidentification of HBB gene mutations.
Hung C, Su Y, Lin C, Chang Y, Chang C, Cheng W, Chen C, Lee C, LinW.
BMC Biotechnol. 8, 62‐70 (2008).
NPHS2 screening with SURVEYOR in Hellenic children withsteroid‐resistant nephrotic syndrome.
Voskarides K, Makariou C, Papagregoriou G, Stergiou N, Printza
N, Alexopoulos E, Elia A, Papachristou F, Pierides A, Georgaki E,
Deltas C.
Pediatr. Nephrol. 23, 1373‐1375 (2008).
Genetic regulation of beta‐ureidopropionase and its possible
implication in altered uracil catabolism.
Thomas, H, Ezzeldin H, Guarcello V, Mattison L, Fridley B and
Diasio R.
Pharmacogenet. Genomics 18; 25‐35 (2008).

3|PageGermline Genetic Screening continued
Screening human genes for small alterations performing an
enzymatic cleavage mismatched analysis (ECMA) protocol.
Vogiatzakis N, Kekou K, Sophocleous C, Kitsiou S, Mavrou A, Bakoula
C, Kanavakis E.
Mol.Biotechnol. 37 12‐9 (2007).
Genetic regulation of dihydropyrimidinase and its possible
implication in altered uracil catabolism.
Thomas H, Ezzeldin H, Guarcello V, Mattison L, Fridley B, Diasio R.
Pharmacogenet Genomics. Nov;17(11):973‐87 (2007).
Development of a rapid, reliable genetic test for
Pseudoxanthoma Elasticum.
Shi Y, Terry S, Terry P, Bercovitch L, Gerard G.
J. Mol. Diagn. 9, 105‐112 (2007).
A new detection method for ATRX gene mutations using amismatch‐specific endonuclease.
Wada T, Fukushima Y, Saitoh S.
Am. J. Med. Genet. A 140, 1519‐1523 (2006).

Mitochondrial DNA Analysis
The link between mitochondrial DNA hypervariable segment I
heteroplasmy and ageing among genetically unrelated Latvians.
Pliss L, Brakmanis A, Ranka R, Elferts D, Krumina A, Baumanis V.
Exp Gerontol. 46, 560‐8 (2011).
Mitochondrial DNA damage and repair in RPE associated withaging and age‐related macular degeneration.
Lin H, Xu H, Liang F, Liang H, Gupta P, Havey A, Boulton M,
Godley B.
Invest. Ophthalmol. Vis. Sci. 52 3521‐3529 (2011).
Surveyor nuclease detection of mutations and polymorphismsof mtDNA in children.
Pilch J, Asman M, Jamroz E, Kajor M, Kotrys‐Puchalska E,
Goss M, Krzak M, Witecka J, Gmiński J, Sieroń AL. Pediatr.
Neurol. 43, 325‐330 (2010).
Strategy in diagnosis of mitochondrial diseases.
Lebre A.
Pathol. Biol (Paris) 58, 353‐356 (2009).
Parkinson's disease brain mitochondria have impaired
respirasome assembly, age‐related increases in distribution ofoxidative damage to mtDNA and no differences inheteroplasmic mtDNA mutation abundance. Arthur C, Morton
S, Dunham L, Keeney P, Bennett J Jr.
Mol. Med. Reports 4, 37‐49 (2009).
Rapid identification of mitochondrial DNA (mtDNA) mutations inneuromuscular disorders by using surveyor strategy.
Bannwarth S, Procaccio V, Rouzier C, Fragaki K, Poole J, Chabrol B,
Desnuelle C, Pouget J, Azulay J, Attarian S, Pellissier J, Gargus J,
Abdenur J, Mozaffar T, Calvas P, Labauge P, Pages M, Wallace D,
Lambert J and Paquis‐Flucklinger V.
Mitochondrion 8, 136‐145 (2008).

Rapid identification of unknown heteroplasmic mutations
across the entire human mitochondrial genome with mismatch‐speci c Surveyor nuclease.
Bannwarth S, Procaccio V, Paquis‐Flucklinger V.
Nat. Protoc. 1, 2037‐2047 (2006).
Surveyor™ Nuclease: A new strategy for a rapid identification ofheteroplasmic mitochondrial DNA mutations in patients withrespiratory chain defects.
Bannwarth S, Procaccio V, Paquis‐Flucklinger V.
Hum. Mutat. 25, 575‐582 (2005).

Plant Biology
Site‐directed mutagenesis in Arabidopsis using custom‐
designed zinc finger nucleases.
Osakabe K, Osakabe Y, Toki S.
Proc. Natl. Acad. Sci. 107, 12034‐12039 (2010).
A Modified TILLING Method for Wheat Breeding.
Dong C, Dalton‐Morgan J, Vincent K, Sharp P.
The Plant Genome 2, 39‐47 (2009).
TILLING in the two‐rowed barley cultivar 'Barke' reveals
preferred sites of functional diversity in the gene HvHox1.
Gottwald S, Bauer P, Komatsuda T, Lundqvist U, Stein N.
BMC Mol. Biol. 2, 258‐271 (2009).
CEL I Nuclease Digestion for SNP Discovery and Marker
Development in Common Bean (Phaseolus vulgaris L.).
Galeano C, Gomez M, Rodriguez L, Blair M.
Croat. Med. J. 49, 381‐394 (2009).
Self‐EcoTILLING to identify single‐nucleotide mutations in
multigene family.
Wang G‐X, Imaizumi T, Li W, Saitoh H, Terauchi R, Ohsako T,
Tominaga T.
Pest Biochem. Physiol, 92, 24‐29 (2008).
TILLMore, a resource for the discovery of chemically induced
mutants in barley.
Talamè V, Bovina R, Sanguineti M, Tuberosa R, Lundqvist U, Salvi S.
Plant Biotechnol. J. 6, 477‐485 (2008).
A structured mutant population for forward and reverse genetics
in Barley (Hordeum vulgare L.).
Caldwell D, McCallum N, Shaw P, Muehlbauer G, Marshall D,
Waugh R.
Plant J. 40, 143‐150 (2004).
Heteroduplex detection with a plant DNA endonuclease forstandard gel electrophoresis.
Scafino M, Pilotto A, Papadimitriou S, Sbalzarini M, Ansaldi S,
Diegoli M, Porcu E, Grasso M, Brega A, Arbustini E.
Transgenics 4, 157‐166 (2004).

4|PageMicrobiology
Generation of targeted Chlamydia trachomatis null mutants. Kari
L, Goheen M, Randall L, Taylor L, Carlson J, Whitmire W, Virok D,
Rajaram K, Endresz V, McClarty G, Nelson D, Caldwell H.
Proc Natl Acad Sci U S A. 108 7189‐93 (2011).
Temperature‐mediated heteroduplex analysis for the detectionof drug‐resistant gene mutations in clinical isolates ofMycobacterium tuberculosis by denaturing HPLC, SURVEYOR
nuclease.
Shi R, Otomo K, Yamada H, Tatsumi T, Sugawara I.
Microbes Infect. 8, 128‐135 (2006).
Localization, mobility and fidelity of retrotransposed Group II
introns in rRNA genes.
Conlan L, Stanger M, Ichiyanagi K, Belfort M.
Nucleic Acids Res. 33, 5262‐5270 (2005).

Surveyor Nuclease use with TALE Nucleases
A do‐it‐yourself protocol for simple transcription activator‐ likeeffector assembly.
Uhde‐Stone C, Gor N, Chin T, Huang J, Lu B.
Biol Proced Online. 15, 3 (2013).
Differential integrity of TALE nuclease genes following
adenoviral and lentiviral vector gene transfer into human cells.
Holkers M, Maggio I, Liu J, Janssen J, Miselli F, Mussolino C,
Recchia A, Cathomen T, Gonçalves M
Nucleic Acids Res. 2012 Dec 28. [Epub ahead of print]
Non‐transgenic genome modifications in a hemimetabolous
insect using zinc‐finger and TAL effector nucleases.
Watanabe T, Ochiai H, Sakuma T, Horch H, Hamaguchi, N,
Nakamura T, Bando T, Ohuchi H, Yamamoto T, Noji S, Mito T Nat
Commun 3, 1017 (2012).
A transcription activator‐like effector toolbox for genome
engineering.
Sanjana N; Cong L; Zhou Y, Cunniff M, Feng G, Zhang F
Nat Protoc 7 171‐192 (2012).

Genetic mutation of recombination activating Gene 1 in Dahl
salt‐sensitive rats attenuates hypertension and renal damage.
Mattson D, Lund H, Guo C, Rudemiller N, Geurts A, Jacob H Am J
Physiol Regul Integr Comp Physiol. 2013 Jan 30. [Epub ahead ofprint]
Chromatin structure of two genomic sites for targeted transgene
integration in induced pluripotent stem cells and hematopoietic
stem cells.
van Rensburg R, Beyer I, Yao X, Wang H, Denisenko O, Li Z,
Russell D, Miller D, Gregory P, Holmes M, Bomsztyk K, Lieber A
Gene Ther. 20, 201‐14 (2013).
RNA‐programmed genome editing in human cells.
Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J.
Elife. 2, e00471 (2013).
A foundation for universal T‐cell based immunotherapy: T cells
engineered to express a CD19‐specific chimeric‐antigen‐receptor and eliminate expression of endogenous TCR.
Torikai H, Reik A, Liu P, Zhou Y, Zhang L, Maiti S, Huls H, Miller J,
Kebriaei P, Rabinovitch B, Lee D, Champlin R, Bonini C, Naldini L,
Rebar E, Gregory P, Holmes M, Cooper L
Blood. 119, 5697‐705 (2012).
Biallelic knockout of the α‐1,3 galactosyltransferase gene inporcine liver‐derived cells using zinc finger nucleases.
Li P, Estrada J, Burlak C, Tector A
J Surg Res. 2012 Jul 3. [Epub ahead of print]
Zinc‐finger nucleases: how to play two good hands.
Isalan M
Nat Methods. 9, 32‐4 (2011).
Targeted gene knockout by direct delivery of zinc‐finger
nuclease proteins.
Gaj T, Guo J, Kato Y, Sirk S, Barbas C
Nat Methods. 9, 805‐7 (2012).
Synthetic zinc finger nuclease design and rapid assembly.
Osborn M, DeFeo A, Blazar B, Tolar J.
Hum Gene Ther. 22, 1155‐65 (2011).

Knockout rats generated by embryo microinjection of TALENs.
Tesson L, Usal C, Ménoret S, Leung E, Niles B, Remy S, Santiago Y,
Vincent A, Meng X, Zhang L, Gregory P, Anegon I, Cost G
Nat Biotechnol. 29, 695–696 (2011).

Engineering HIV‐Resistant Human CD4+ T Cells with CXCR4‐Specific Zinc‐Finger Nucleases.
Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, et al.
PLoS Pathog 7, e1002020 (2011)

A TALE nuclease architecture for efficient genome editing. Miller
J, Tan S, Qiao G, Barlow KA, Wang J, Xia D, Meng X, Paschon D,
Leung E, Hinkley S, Dulay G, Hua K, Ankoudinova I, Cost G, Urnov
F, Zhang H, Holmes M, Zhang L, Gregory P, Rebar E.
Nat. Biotechnol. 29, 143‐148 (2011).

DNA Ligase III Promotes Alternative Nonhomologous End‐
Joining during Chromosomal Translocation Formation.
Simsek D, Brunet E, Wong SY‐W, Katyal S, Gao Y, et al.
PLoS Genet 7, e1002080. (2011)

Surveyor Nuclease use with Zinc Finger Nucleases
Efficient Clinical Scale Gene Modification via Zinc Finger NucleaseTargeted Disruption of the HIV Co‐Receptor CCR5.
Maier D, Brennan A, Jiang S, Binder‐Scholl G, Lee G, Plesa G, Zheng
Z, Cotte J, Carpenito C, Wood T, Spratt S, Ando D, Gregory P,
Holmes M, Perez E, Riley J, Carroll R, June C, Levine B
Hum Gene Ther. 2013 Jan 29. [Epub ahead of print]

Efficient generation of a biallelic knockout in pigs using zinc‐finger nucleases.
Hauschild J, Petersen B, Santiago Y, Queisser A, Carnwath J,
Lucas‐Hahn A, Zhang L, Meng X, Gregory P, Schwinzer R, Cost G,
Niemann H.
Proc Natl Acad Sci U S A. 108, 12013‐7 (2011).

5|PageSurveyor Nuclease use with Zinc Finger Nucleases
continued
Gene Editing of Human Embryonic Stem Cells via an Engineered
Baculoviral Vector Carrying Zinc‐finger Nucleases. Lei Y, Lee C‐L,
Joo K‐I, Zarzar J, Liu Y, Dai B, Fox V, Wang P.
Mol Ther. 19, 942‐950 (2011).
Gene targeting to the ROSA26 locus directed by engineered zincfinger nucleases.
Perez‐Pinera P, Ousterout D, Brown M, Gersbach C.
Nucleic Acids Res. 2011 Dec 14. [Epub ahead of print]
Transient cold shock enhances zinc‐finger nuclease‐mediatedgene disruption.
Doyon Y, Choi V, Xia D, Vo T, Gregory P, Holmes M.
Nat Methods 7, 459‐460 (2010).
Knockout of exogenous EGFP gene in porcine somatic cells
using zinc‐finger nucleases.
Watanabe M, Umeyama K, Matsunari H, Takayanagi S,
Haruyama E, Nakano K, Fujiwara T, Ikezawa Y, Nakauchi H,
Nagashima H.
Biochem. Biophys. Res. Commun. 402, 14‐18 (2010).
Generation of gene‐specific mutated rats using zinc‐finger
nucleases.
Geurts A, Cost G, Rémy S, Cui X, Tesson L, Usal C, Ménoret S,
Jacob H, Anegon I, Buelow R.
Methods Mol. Biol. 597, 211‐225 (2010).
Knockout rats via embryo microinjection of zinc‐finger
nucleases.
Geurts A, Cost G, Freyvert Y, Zeitler B, Miller J, Choi V, Jenkins S,
Wood A, Cui X, Meng X, Vincent A, Lam S, Michalkiewicz M,
Schilling R, Foeckler J, Kalloway S, Weiler H, Ménoret S, Anegon I,
Davis G, Zhang L, Rebar E, Gregory P, Urnov F, Jacob J, Buelow R.
Science 325, 433 (2009).

Synthetic Gene Error Correction
Enrichment of Error‐Free Synthetic DNA Sequences by CEL I
Nuclease.
Hughes R, Miklos A, Ellington A
Curr Protoc Mol Biol Chpt 3 Unit 3.24 (2012).
Enzymatic on‐Chip Enhancement for High Resolution
Genotyping DNA Microarrays.
Schulze H, Barl T, Vase H, Baier S, Thomas P, Giraud G, Crain J,
Bachmann TT.
Anal Chem. 84, 5080‐4 (2012).
Error correction of microchip synthesized genes using Surveyor
nuclease.
Saaem I, Ma S, Quan J, Tian J.
Nucleic Acids Res. 40, e23 (2012).

Parallel on‐chip gene synthesis and application to
optimization of protein expression.
Quan J, Saaem I, Tang N, Ma S, Negre N, Gong H, White KP,
Tian J.
Nat Biotechnol. 29 449‐52 (2011).
Endonucleases: tools to correct the dystrophin gene.
Rousseau J, Chapdelaine P, Boisvert S, Almeida L, Corbeil J,
Montpetit A, Tremblay J.
J Gene Med. 13, 522‐37 (2011).

Other Surveyor Nuclease Applications
Multiplex genome engineering using CRISPR/Cas systems.
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X,
Jiang W, Marraffini LA, Zhang F.
Science. 339, 819‐23 (2013)
A simple, high sensitivity mutation screening using
Ampligase mediated T7 endonuclease I and Surveyor
nuclease with microfluidic capillary electrophoresis. Huang
M, Cheong W, Lim L, Li M
Electrophoresis 2012 Mar 33(5) 788‐796
A highly sensitive and specific biosensor for ligation‐ andPCR‐free detection of MicroRNAs.
Gao Z, Peng Y.
Biosens Bioelectron. 26, 3768‐3773 (2011).
s‐RT‐MELT: a novel technology for mutation screening.
Li J, Makrigiorgos GM.
Methods Mol Biol. 653, 207‐19 (2010).
A rapid and general assay for monitoring endogenous genemodification.
Guschin D, Waite A, Katibah G, Miller J, Holmes M, Rebar E.
Methods Mol Biol. 649, 247‐56 (2010).
High‐throughput identification of mutations using a combinationof CEL I fragmentation and SAGE technology.
Zhang C, Li Y, Wang X, Zhang L, Li X, Wang Y, Xu S.
Genet Test Mol Biomarkers 13, 97‐103 (2009).
Endonucleolytic mutation analysis by internal labeling (EMAIL).
Cross M, Waters D, Lee L, Henry R.
Electrophoresis 29, 1291‐1301 (2008).
Development of a simple and highly sensitive mutation
screening system by enzyme mismatch cleavage with optimized
conditions for standard laboratories.
Tsuji T, Niida Y.
Electrophoresis 29, 1473‐83 (2008).
s‐RT‐MELT for rapid mutation scanning using enzymatic
selection and real time DNA‐melting: new potential for
multiplex genetic analysis.
Li J, Berbeco R, Distel R, Jänne P, Wang L, Makrigiorgos GM.
Nucleic Acids Res. 35, e84 (2007).

6|PageOtheer SURVEYOR
R Nuclease Applications
A
continued
Surveeyor nuclease‐b
based genotyping of SNPs.
Mitan
ni N, Tanaka S, OkamotoO
Y.
Clin. LLab. 52, 385‐6 (2006).
(
A metthod for clone sequence confirmation using a
mism
match‐specific DNA
D endonucle
ease.
Qiu P,, Shandilya H, Gerard
G
GF.
Mol. B
Biotechnol. 29, 11‐18 (2005).

Improvving specificityy of DNA hybrid
dization‐based methods.
Chalayya T, Gogvadze EE, Buzdin A, Kovvalskaya E, Sverdlov ED.
Nucleicc Acids Res. 32,, e130 (2004).
Mutatiion detection u
using Surveyor™ nuclease.
Qiu P, SShandilya H, D’’Alessio JM, O’C
Connor K, Duroocher J,
Gerardd GF.
Biotechhniques 36, 7022‐707 (2004).

www.IDTDN
NA.comm/Surveeyor
For quuestions or additional assistance,apleasepcontaact IDT Custo
omer Care aat:
USA & Canada
custcare@idtdna.com
1–800––328–2661

Europ
pe
eutecchsupport@idttdna.com+32 (00) 16 28 22 60

Assia Pacificassiacustcare@iddtdna.com+6
65 6775 9187

A
Australia
aauscustcare@iidtdna.com
11800 092 259

Web C
Chat at: www.iidtdna.com©2014 Integrated DNA Te
echnologies, Inc. All
A rights reserved. Trademarks contaained herein are t he property of Inttegrated DNA Techhnologies, Inc. or ttheir respective
owners. For specific tradeemark and licensing information, seee www.idtdna.com
m/trademarks.
Surveyor products are covvered by multiple IDT patents and arre sold by IDT und
der exclusive licensse to U.S. Patents 6,391,577, 5,869,245. This product is sold for non‐commerrcial, research use only. Any non‐clin
nical, commercial use, including withhout limitation thee use of any Surveeyor product in thee manufacture of nucleic acidproductss of any type, requuires a separate liccense from IDT. An
ny clinical use of any Surveyor produuct requires a sep arate license fromm Transgenomic, th
he exclusive
licensee of Surveyor products in the clinical and diagnostic fie
elds. Surveyor is a registered tradem
mark of IDT.

7|Page